Eisai Projects Leqembi Revenue Growth

Eisai, in collaboration with BioArctic, announced a projected revenue of JPY 143.5 billion (approximately SEK 8.4 billion) for their Alzheimer's drug, Lecanemab, for fiscal year 2026 (April 2026 - March 2027). This represents a 63% growth compared to the previous year and is expected to generate approximately SEK 880 million in royalties for BioArctic. Lecanemab, developed based on Professor Lars Lannfelt's work, is approved in 53 countries and is under regulatory review in 6 others. Recent developments include the approval of intravenous maintenance dosing in 7 countries, including the United Kingdom, China, the United States, and Japan, and the approval of subcutaneous dosing with an autoinjector in the United States. New drug applications for subcutaneous formulation were submitted in Japan and accepted in China, with the latter designated for priority review. The United States — Food and Drug Administration also granted Priority Review to Eisai's supplemental Biologics License Application for Lecanemab Iqlik, with a PDUFA date of August 24, 2026. Additionally, Lecanemab was included in China's 'Commercial Insurance Innovative Drug List'.